Phase I study of OSI-211 (liposomal lurtotecan) in combination with liposomal doxorubicin (LD) every 3 weeks in patients (pts) with advanced solid tumors; final analysis suggests benefit in refractory ovarian cancer (OC)
Journal of Clinical Oncology（2005）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要